3 recruiting, 2 not yet recruiting, 2 unknown. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Xiangdong Cheng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer Tislelizumab, SOX or CAPOX regimen - Gastric Cancer Stage | Phase 3 | Not yet recruiting | Xiangdong Cheng | 470 | 2025-07-20 | 2025-07-16 |
| QL1706 Combined With SOX Used in Theperioperative Treatment QL1706 combined with SOX - Gastric Cancers, Esophagogastric Junction Cancers | Phase 1 / Phase 2 | Recruiting | Xiangdong Cheng | 54 | 2025-03-21 | 2025-06-17 |
| Study of IBI363 in Patients with Advanced First-line Gastric Cancer IBI363 - IBI363 + Chemotherapy | Phase 1 | Recruiting | Xiangdong Cheng | 40 | 2024-10-15 | 2024-11-20 |
| A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established Abdominal Neoplasm | Recruiting | Xiangdong Cheng | 100000 | 2024-07-01 | 2024-09-26 | |
| Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. Tislelizumab, SOX/XELOX - Gastric Cancer | Phase 2 | Not yet recruiting | Xiangdong Cheng | 134 | 2024-04-25 | 2024-04-19 |
| Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer. Peripheral blood, tougue coating, saliva, and feces - Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Unknown | Xiangdong Cheng | 150 | 2024-03-25 | 2024-10-15 | |
| Nivolumab Combined With SOX Used in the Perioperative Treatment nivolumab combined with SOX - Immune Suppression, Gastric Cancer | Phase 2 | Unknown | Xiangdong Cheng | 46 | 2022-11-03 | 2024-07-09 |
Stomach Neoplasms (3) · Abdominal Neoplasms (1)
tislelizumab (2) · Defecation (1) · XELOX (1)
China (7)
Cheng Xiangdong (1)